x | GenAIz unlocks the value of life sciences enterprise data, connecting systems with AI-powered intelligent solutions so teams can act with clarity, confidence, and speed. To do this, we’ve created a novel, ethical, and data compliant AI solution that massively increases workflow efficiency across pharmaceutical and life sciences applications.
Daxiang Biotech
Daxiang Biotech is a leading innovator in organoid-on-a-chip technologies in China and a global provider of integrated microphysiological systems (MPS) solutions for drug discovery, translational research, and precision medicine. Founded in 2018, the company has established a fully integrated, end-to-end platform spanning design, modeling, R&D, manufacturing, and application of human-relevant in vitro systems. Powered by its core technology framework—Organoid-on-a-Chip + AI + Automation—Daxiang develops proprietary instruments, chips, reagents, and advanced human-relevant models to help global life sciences partners improve preclinical decision-making and accelerate development timelines. At the core of its technology is the IBAC® (Integrated Biomimetic Array Chip) platform, which integrates stem cell biology, organoid science, and microfluidics to recreate physiologically relevant human tissue environments in vitro. Based on this platform, Daxiang has developed 50+ organoid culture kits and 100+ humanized physiological and disease models across oncology, liver, gastrointestinal, kidney, brain, and cardiovascular applications. Daxiang’s technologies have been validated by third-party institutions and adopted by leading pharmaceutical companies, biotechnology companies, hospitals, and research institutes. The company has supported multiple IND-enabling programs, helping partners improve translational predictability and reduce reliance on animal models in selected applications. Daxiang Biotech is actively seeking global partnerships with pharmaceutical and biotech companies, CRO/CDMO organizations, research institutions, distributors, and strategic investors. Key collaboration interests include drug discovery services, translational model co-development, precision medicine applications, regional commercialization, and AI-enabled next-generation preclinical platforms.
Coherence Biotech Co. Ltd.
Coherence Bio is a lab automation company developing tools to accelerate AI based drug discovery, through end-to-end automation of cell-based testing.
Cleveland Clinic Innovations
We are more than a tech transfer office. We are a medical innovations powerhouse. Cleveland Clinic Innovations brings the best ideas from the brightest minds in medicine to patients around the world. We connect inventors and their ideas with strategic industry partners to create products that transform the future of healthcare. Cleveland Clinic is changing healthcare for patients around the world. https://39682636.hs-sites.com/bio-home | x | Cleveland Clinic Innovations (CCI) is dedicated to turning caregiver-inspired ideas into medical breakthroughs that meaningfully improve patient lives. Since 2000, our team has transformed over 900 technologies into licensed products, secured more than 2,800 patents, and launched over 100 spin-off companies, achieving 28 successful exits. Our multidisciplinary team works side-by-side with clinicians, researchers, and industry to guide innovations through every stage, from concept to licensing, startup formation, clinical validation, and scaling. We’re more than a technology transfer office, we’re strategic partners in transforming healthcare innovation. Whether it’s harnessing AI for diagnostics, pioneering digital health solutions, developing novel therapeutics, or creating advanced drug delivery systems, we ensure that innovative ideas become practical solutions impacting patient care globally. Technologies available for licensing include: · Digital Health · Drug Delivery · Diagnostics · Therapeutics · Research Tools What Makes Cleveland Clinic Innovations Unique? · Direct clinician and researcher access for rapid, real-world healthcare insights. · Robust clinical validation and real-world data-driven innovation within a globally recognized health system. · Comprehensive IP management, strategic licensing expertise, and proven healthcare startup incubation. Why partner with Cleveland Clinic Innovations? · Expert guidance through healthcare startup creation, technology transfer, and commercialization pathways. · Integrated access to world-class clinical, regulatory, and research infrastructure. · Global presence supporting innovations across markets (U.S., London, Abu Dhabi, Canada). Together, we can accelerate healthcare innovation and create meaningful patient impact. Explore our technologies and partner with us: https://my.clevelandclinic.org/innovations
CALYSTA NV
CALYSTA positions itself as a key player in IP, with some of the most experienced and passionate professionals, all eager to exceed your expectations. Our attorneys not only manage the defense and protection of your intellectual property assets extremely well, they also pride themselves on thoroughly understanding the operations and strategy of your company. Doing so, they ensure to tailor their services to your actual needs. CALYSTA is a new style and modern Intellectual Property (IP) firm. | Calysta is a Belgian IP firm helping life sciences innovators evaluate and protect innovation, and serving as a trusted European patent partner
BloodScan Biotech Inc.
BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
Adlib Software
Adlib is the accuracy authority in AI-driven document automation for high-stakes, regulated industries. As the critical layer in front of IDP systems, LLMs, and RAG pipelines, Adlib ingests messy, multi-format content and transforms it into AI-ready, machine-navigable pipelines. The platform normalizes file types, applies fidelity-preserving rendering and advanced OCR, classifies and chunks content with citation anchors, enriches it with metadata, extracts information into structured data contracts, and validates outputs against each organization’s business and compliance rules. This results in compliant, searchable outputs and high-quality structured data that downstream systems can trust. Across Life Sciences, Energy, Insurance, Financial Services, and other regulated sectors, enterprises rely on Adlib to reduce human-in-the-loop reviews, increase retrieval precision and model accuracy, accelerate decision-making, and lower processing costs. For more than two decades, organizations such as Pfizer, Swiss Re, IAG, and JP Morgan have trusted Adlib to turn unstructured content into reliable, audit-ready data that safeguards compliance, drives performance, and ensures every decision is precise and AI-ready.